A neuroinformatics study describing molecular interaction of cisplatin with acetylcholinesterase: A plausible cause for anticancer drug induced neurotoxicity

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 2, 2014, Pages 265-270

  Baig, Mohd Hassan ^a   Rizvi, Syed Mohd Danish ^a   Shakil, Shazi ^a   Kamal, Mohammad Amjad ^b   Khan, Saif ^a  

^a INTEGRAL UNIVERSITY   (India)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Accessible surface area; Acetylcholinesterase; Cisplatin; Docking

Indexed keywords

ACETYLCHOLINESTERASE; CISPLATIN; ANTINEOPLASTIC AGENT; CHOLINESTERASE INHIBITOR; PROTEIN BINDING;

ACCESSIBLE SURFACE AREA; AMINO ACID SEQUENCE; ARTICLE; ENZYME ACTIVITY; EXPERIMENTAL STUDY; MOLECULAR DOCKING; MOLECULAR INTERACTION; NEUROTOXICITY; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; RECEPTOR BINDING ASSAY; X RAY CRYSTALLOGRAPHY; BRAIN; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; ENZYMOLOGY; HUMAN; HYDROGEN BOND; METABOLISM;

ACETYLCHOLINESTERASE; ANTINEOPLASTIC AGENTS; BRAIN; CHOLINESTERASE INHIBITORS; CISPLATIN; HUMANS; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING;

EID: 84912113873     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660143     Document Type: Article

References (38)

1. Shakil S, Kamal MA, Tabrez S, et al. Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study. CNS Neurol Disord Drug Targets 2012; 11(2): 142-7.
2. Shakil S. Addressing Clinical Microbiology Problems through Bioinformatics Tools. LAP Lambert Academic Publishing 2009.
3. Shakil S, Khan AU. Infected foot ulcers in male and female diabetic patients: a clinico-bioinformative study. Ann Clin Microbiol Antimicrob 2010; 14(9): 2.
4. Shakil S, Khan AU. Interaction of CTX-M-15 enzyme with cefotaxime: a molecular modelling and docking study. Bioinformation 2010; 30(10): 468-72.
5. Florea AM, Büsselberg D. Metals and breast cancer: risk factors or healing agents? J Toxicol 2011; 2011: 159619.
6. Giaccone G. Treatment of thymoma and thymic carcinoma. Ann Oncol 2000; 11(3): 245-6.
7. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 2002; 42(3): 317-25.
8. Shah N, Dizon DS. New-generation platinum agents for solid tumors. Future Oncol 2009; 5(1): 33-42.
9. Günes DA, Florea AM, Splettstoesser F, Büsselberg D. Coapplication of arsenic trioxide (As2O3) and Cisplatin (CDDP) on human SY-5Y neuroblastoma cells has differential effects on the intracellular calcium concentration ([Ca2+]i) and cytotoxicity. Neurotoxicology 2009; 30(2): 194-202.
10. Florea AM, Büsselberg D. Occurrence, use and potential toxic effects of metals and metal compounds. Biometals 2006; 19(4): 419-27.
11. Tsang RY, Al-Fayea T, Au HJ. Cisplatin overdose: toxicities and management. Drug Saf 2009; 32(12): 1109-22.
12. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009; 8(1): 10-6.
13. Stillman M, Cata JP. Management of chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 2006; 10(4): 279-87.
14. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is Cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59(4): 657-63.
15. Yang XL, Wang AHJ. Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther 1999; 83: 181-215.
16. Dzagnidze A, Katsarava Z, Makhalova J, et al. Repair capacity for platinum-DNA adducts determines the severity of Cisplatin-induced peripheral neuropathy. J Neurosci 2007; 27(35): 9451-7.
17. Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and Cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006; 27(6): 992-1002.
18. Perez RP. Cellular and molecular determinants of Cisplatin resistance. Eur J Cancer 1998; 34(10): 1535-42.
19. Okoronkwo NE, Echeme JO, Onwuchekwa EC. Cholinesterase and bacterial inhibitory activities of Stachytarpheta cayennensis. Acad Res 2012; 2(3): 209-17.
20. Greenblatt HM, Dvir H, Silman I, Sussman JL. Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease. J Mol Neurosci 2003; 20(3): 369-83.
21. Al-Jafari AA, Kamal MA, Duhaiman AS. The mode of inhibition of human erythrocyte membrane-bound acetylcholinesterase by Cisplatin in vitro. J Enzyme Inhib 1995; 8(4): 281-9.
22. Al-Jafari AA, Kamal MA, Alhomida AS. On the inhibition of camel retina acetylcholinesterase activity by cycloheximide in vitro. Cell Biol Toxicol 1998; 14(3): 167-74.
23. Al-Jafari AA, Kamal MA. Investigation of the effect of tetrahydroaminoacridine on turnover kinetics of camel (Camelus dromedarius) retina acetylcholinesterase. Biochem Mol Biol Int 1996; 39(5): 917-22.
24. Kamal MA. Characterization of human erythrocyte membranebound acetylcholinesterase inhibition by Cisplatin at reversible phase. Anticancer Res 1996; 16(6B): 3725-30.
25. Shakil S, Khan R, Tabrez S, et al. Interaction of human brain acetylcholinesterase with cyclophosphamide: a molecular modeling and docking study. CNS Neurol Disord Drug Targets 2011; 10(7): 845-8.
26. Shakil S, Kamal MA, Tabrez S, et al. Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholineesterase: a docking study. CNS Neurol Disord Drug Targets 2012; 11(2): 142-7.
27. Brooks BR, Bruccoleri RE, Olafson BD, Swaminathan S, Karplus M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J Comp Chem 2004; 4(2): 187-217.
28. Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithim with a description of desolvation. J Mol Biol 1995; 245: 43-53.
29. Hubbard SJ, Thornton JM. NACCESS, Computer Program, Department of Biochemistry and Molecular Biology; University College London 1993.
30. Wang R, Lai L, Wang S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J Comput Aided Mol Des 2002; 16(1): 11-26.
31. Silman I, Sussman JL. Acetylcholinesterase: 'classical' and 'nonclassical' functions and pharmacology. Curr Opin Pharmacol 2005; 5(3): 293-302.
32. Silman I, Sussman JL. Acetylcholinesterase: how is structure related to function? Chem Biol Interact 2008; 175(1): 3-10.
33. Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991; 253(5022): 872-9.
34. Raves ML, Harel M, Pang YP, et al. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat Struct Biol 1997; 4(1): 57-63.
35. Samanta U, Bahadur RP, Chakrabarti P. Quantifying the accessible surface area of protein residues in their local environment. Protein Eng 2002; 15(8): 659-67.
36. Lo Conte L, Chothia C, Janin J. The atomic structure of proteinprotein recognition sites. J Mol Biol 1999; 285(5): 2177-98.
37. Song SQ, Zhang GN. Therapeutic evaluation of Cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia. Zhonghua Fu Chan Ke Za Zhi 2012; 47(8): 571-6.
38. Mendonça LM, da Silva Machado C, Teixeira CC, et al. Curcumin reduces Cisplatin-induced neurotoxicity in NGF-differentiated PC12 cells. Neurotoxicology 2012; 34: 205-11.